Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades VistaGen Therapeutics to Hold

Maxim Group Downgrades VistaGen Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

byBenzinga Newsdesk

July 26, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

Robinhood Markets Stock Is Ripping Higher Wednesday: What’s Going On?

By Adam Eckert

February 14, 9:45 AM

Robinhood Markets Inc (NASDAQ:HOOD) shares are trading higher Wednesday after the company reported strong quarterly results that included a surprise profit.

BTC

United Airlines CEO Says For What It’s Worth, We Are Planning For A Mild Recession Next Year

By Benzinga Newsdesk

December 13, 3:15 PM

- Reuters

UAL

MetLife-Spinoff Brighthouse Financial Impresses Analyst With Business Mix Improvements

By Priya Nigam

June 17, 12:47 PM

Analyst upgrades Brighthouse Financial, citing gradual business mix improvement and strong capital position. Stock has lost 23% YTD but trading at reasonable free cash flow yield.

BHF

Barclays Maintains Equal-Weight on Colgate-Palmolive, Raises Price Target to $80

By Benzinga Newsdesk

January 3, 9:39 AM

Barclays analyst Chris Carey maintains Colgate-Palmolive (NYSE:CL) with a Equal-Weight and raises the price target from $75 to $80.

Maxim Group Downgrades VistaGen Therapeutics to Hold

Related Posts

Robinhood Markets Stock Is Ripping Higher Wednesday: What’s Going On?

United Airlines CEO Says For What It’s Worth, We Are Planning For A Mild Recession Next Year

MetLife-Spinoff Brighthouse Financial Impresses Analyst With Business Mix Improvements

Barclays Maintains Equal-Weight on Colgate-Palmolive, Raises Price Target to $80